Alembic Pharmaceuticals Limited

NSEI:APLLTD Stock Report

Market Cap: ₹206.0b

Alembic Pharmaceuticals Valuation

Is APLLTD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of APLLTD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: APLLTD (₹1047.8) is trading above our estimate of fair value (₹544.45)

Significantly Below Fair Value: APLLTD is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for APLLTD?

Key metric: As APLLTD is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for APLLTD. This is calculated by dividing APLLTD's market cap by their current earnings.
What is APLLTD's PE Ratio?
PE Ratio31.8x
Earnings₹6.47b
Market Cap₹205.96b

Price to Earnings Ratio vs Peers

How does APLLTD's PE Ratio compare to its peers?

The above table shows the PE ratio for APLLTD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average47.1x
CONCORDBIO Concord Biotech
67.8x26.9%₹222.3b
530019 Jubilant Pharmova
29.2x5.5%₹173.0b
524742 Caplin Point Laboratories
36.8x13.6%₹181.8b
ERIS Eris Lifesciences
54.5x30.7%₹189.7b
APLLTD Alembic Pharmaceuticals
31.8x21.5%₹206.0b

Price-To-Earnings vs Peers: APLLTD is good value based on its Price-To-Earnings Ratio (31.8x) compared to the peer average (47.1x).

Price to Earnings Ratio vs Industry

How does APLLTD's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.7xn/aUS$72.90m
524652 Ind-Swift
2.8xn/aUS$17.91m
No more companies available in this PE range
APLLTD 31.8xIndustry Avg. 34.7xNo. of Companies20PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: APLLTD is good value based on its Price-To-Earnings Ratio (31.8x) compared to the Indian Pharmaceuticals industry average (34.7x).

Price to Earnings Ratio vs Fair Ratio

What is APLLTD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

APLLTD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31.8x
Fair PE Ratio42.1x

Price-To-Earnings vs Fair Ratio: APLLTD is good value based on its Price-To-Earnings Ratio (31.8x) compared to the estimated Fair Price-To-Earnings Ratio (42.1x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst APLLTD forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₹1,047.80
₹1,161.92
+10.9%
12.6%₹1,412.00₹895.00n/a12
Dec ’25₹1,092.20
₹1,161.92
+6.4%
12.6%₹1,412.00₹895.00n/a12
Nov ’25₹1,127.05
₹1,092.58
-3.1%
13.0%₹1,396.00₹837.00n/a12
Oct ’25₹1,191.95
₹1,092.17
-8.4%
13.0%₹1,396.00₹837.00n/a12
Sep ’25₹1,059.10
₹1,056.33
-0.3%
14.3%₹1,396.00₹837.00n/a12
Aug ’25₹1,212.50
₹985.08
-18.8%
9.9%₹1,229.00₹845.00n/a13
Jul ’25₹923.50
₹983.54
+6.5%
9.8%₹1,229.00₹845.00n/a13
Jun ’25₹923.10
₹980.31
+6.2%
10.1%₹1,229.00₹845.00n/a13
May ’25₹999.60
₹937.69
-6.2%
9.7%₹1,143.00₹770.00n/a13
Apr ’25₹1,008.95
₹901.08
-10.7%
7.3%₹1,023.00₹770.00n/a13
Mar ’25₹1,055.00
₹888.14
-15.8%
8.9%₹1,023.00₹720.00n/a14
Feb ’25₹955.55
₹769.67
-19.5%
13.0%₹915.00₹515.00n/a15
Jan ’25₹765.90
₹742.44
-3.1%
15.2%₹915.00₹515.00n/a16
Dec ’24₹751.15
₹742.44
-1.2%
15.2%₹915.00₹515.00₹1,092.2016
Nov ’24₹712.55
₹723.07
+1.5%
15.1%₹895.00₹515.00₹1,127.0515
Oct ’24₹784.45
₹715.33
-8.8%
14.9%₹895.00₹515.00₹1,191.9515
Sep ’24₹770.50
₹715.33
-7.2%
14.9%₹895.00₹515.00₹1,059.1015
Aug ’24₹775.50
₹598.20
-22.9%
9.0%₹704.00₹515.00₹1,212.5015
Jul ’24₹636.40
₹590.87
-7.2%
8.7%₹704.00₹515.00₹923.5015
Jun ’24₹548.85
₹586.94
+6.9%
8.7%₹704.00₹515.00₹923.1016
May ’24₹556.15
₹601.25
+8.1%
7.7%₹704.00₹540.00₹999.6016
Apr ’24₹496.35
₹603.44
+21.6%
7.3%₹704.00₹540.00₹1,008.9516
Mar ’24₹507.25
₹630.24
+24.2%
14.5%₹944.00₹550.00₹1,055.0017
Feb ’24₹539.65
₹674.63
+25.0%
14.1%₹944.00₹563.00₹955.5516
Jan ’24₹572.90
₹676.50
+18.1%
14.2%₹944.00₹563.00₹765.9016
Dec ’23₹594.60
₹682.75
+14.8%
13.4%₹944.00₹563.00₹751.1516

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 04:47
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alembic Pharmaceuticals Limited is covered by 26 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Sarabjit NangraAngel Broking Private Limited
null nullAntique Stockbroking Ltd.
Vijayaraghavan SwaminathanAvendus Spark